A5051737896- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Medical Imaging Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Peptidase Inhibition and Analysis
- Medical Imaging and Pathology Studies
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Advanced Radiotherapy Techniques
- MRI in cancer diagnosis
- Pancreatic and Hepatic Oncology Research
- Cancer Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Radiation Dose and Imaging
- Lung Cancer Diagnosis and Treatment
Saarland University
2015-2024
ORCID
2024
Klinik und Poliklinik für Nuklearmedizin
2004-2021
Universitätsklinikum des Saarlandes
2015-2021
University Hospital Bonn
2006-2018
University Hospital Schleswig-Holstein
2018
University of Lübeck
2018
University of Bonn
2003-2017
Universitäts-Frauenklinik des Saarlandes
2016
Fondazione IRCCS Istituto Nazionale dei Tumori
2014
A multicenter analysis was conducted to evaluate the main prognostic factors driving survival after radioembolization using yttrium-90-labeled resin microspheres in patients with hepatocellular carcinoma at eight European centers. In total, 325 received a median activity of 1.6 GBq between September 2003 and December 2009, predominantly as whole-liver (45.2%) or right-lobe (38.5%) infusions. Typically, were Child-Pugh class (82.5%), had underlying cirrhosis (78.5%), good Eastern Cooperative...
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified PSMA PET imaging. Promising results PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations targeting molecules radiolabels. Definitive evidence safety efficacy [177Lu]Lu-PSMA-617 combination standard-of-care has demonstrated metastatic...
Rationale: Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which may provide advantages by emitting additional Auger and conversion electrons.In this pilot study, we present preliminary dosimetry data [ Tb]Tb-PSMA-617 RLT a direct comparison with 177 Lu]Lu-PSMA-617.Method: Six patients metastatic castration-resistant prostate cancer (mCRPC) underwent treatment Lu]Lu-PSMA-617...
Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially regard to the impact of Ki-67 index. Using a single-center analysis, we aimed establish predictors survival. <b>Methods:</b> We retrospectively analyzed consecutive cohort 74 who had metastatic GEP NET and underwent PRRT <sup>177</sup>Lu-octreotate (mean activity 7.9 GBq per cycle, at 4 treatment cycles standard intervals 3...
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT). The aim of this study was to investigate incidence, severity, and reversibility long-term hematotoxicity a large cohort patient undergoing PRRT with (177)Lu-octreotate for metastatic neuroendocrine tumors. impact potential risk factors, including initial cytopenia, advanced bone disease, previous chemotherapy, cumulative administered activity, protective effects splenectomy were particular...
Preliminary data from retrospective analyses and recent large randomized controlled trials suggest safety efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited on this modality have been published regarding samples treated everyday practice.We analyzed prospectively collected registry lutetium-177 (177Lu)-PSMA-617 RLT 254 consecutive mCRPC seen academic practice. Since...
Rationale: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted 177 Lu radioligand therapy in metastatic castration-resistant prostate carcinoma (mCRPC), some patients do not respond and other with initially good response develop resistance to this treatment.In study, we investigated molecular imaging biochemical responses after a single cycle [ 225 Ac]Ac-PSMA-617/[ Lu]Lu-PSMA-617 tandem who had progressed on monotherapy.Methods: Seventeen mCRPC were included...
We investigated the effect of repeated bone-targeted therapy with rhenium-188 hydroxyethylidenediphosphonate (HEDP) in patients progressive, hormone-resistant prostate carcinoma and bone pain. The aim this study was to determine pain palliation antitumor HEDP treatments.Sixty-four were randomly assigned one two groups for radionuclide HEDP; group A received a single injection, B injections (interval, 8 weeks). After therapy, followed-up by assessment clinical outcome until death.In both...
Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for treating primary and metastatic liver cancer, requires appropriate planning to maximize its therapeutic response minimize side effects. (99m)Tc-macroaggregated albumin (MAA) scanning should precede the detect any extrahepatic shunting lung or gastrointestinal tract. Our aim was compare ability of SPECT/CT with that planar imaging SPECT in detection localization (99m)Tc-MAA accumulation evaluate impact...
A relationship between haemophilia and osteoporosis has been suggested, leading to the initiative for a larger study assessing this issue. Bone mineral density (BMD) was measured by osteodensitometry using dual energy X-ray absorptiometry (DEXA) in 62 male patients with severe A; mean age 41 +/- 13.1 years, body mass index (BMI) 23.5 3.6 kg m(-2). Using clinical score suggested World Federation of Hemophilia, all were assessed determine severity their arthropathy. reduced BMD defined as...
The tumor proliferation marker, Ki-67 index, is a well-established prognostic marker in gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging allows whole-body metabolic characterization of metastatic disease. We investigated the impact <sup>18</sup>F-FDG PET inoperable multifocal <b>Methods:</b> Retrospective, dual-center analysis was performed on 89 patients with histologically confirmed, NENs undergoing PET/CT within staging routine. Metabolic (PET-based)...
The skeleton is the most common metastatic site in patients with advanced cancer. Pain a major healthcare problem bone metastases. Bone-seeking radionuclides that selectively accumulate are used to treat cancer-induced pain and prolong survival selected groups of cancer patients. goals these guidelines assist nuclear medicine practitioners in: (a) evaluating who might be candidates for radionuclide treatment metastases using beta-emitting such as strontium-89 (89Sr), samarium-153 (153Sm)...
To address the lack of prospective data on real-life clinical application trans-arterial radioembolization (TARE) in Europe, Cardiovascular and Interventional Radiological Society Europe (CIRSE) initiated observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT).Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients adult treated with TARE Y90 resin microspheres primary or metastatic liver tumours. Patients followed up 24 months after treatment, whereas...